Nanohale AG (ETR:FYB) | WebDisclosure

PRESS RELEASE

published on 04/20/2026 at 06:30, 2 months 8 days ago

Formycon invites to Conference Call on the Results of the Financial Year 2025 and announces Participation in international Investor Conferences in the 2nd Quarter of 2026
Formycon AG to hold Conference Call on Results of FY 2025 and participate in international Investor Conferences in Q2 2026. Details and registration at provided links

Conference Call Investor Conferences Formycon AG Biosimilars Financial Year 2025
BRIEF

published on 04/15/2026 at 19:57, 2 months 12 days ago

Formycon AG annonce des résultats préliminaires améliorés pour l'exercice 2025.

Formycon AG Fonds De Roulement États Financiers Annuels Exercice Financier 2025 EBITDA Du Groupe
BRIEF

published on 04/15/2026 at 19:57, 2 months 12 days ago

Formycon AG Reports Improved Preliminary Figures for 2025 Fiscal Year

Working Capital Annual Financial Statements Formycon AG 2025 Fiscal Year Group EBITDA
PRESS RELEASE

published on 04/15/2026 at 19:52, 2 months 12 days ago

EQS-Adhoc: Formycon AG:
Formycon AG announces improved preliminary figures for the 2025 fiscal year, including adjusted EBITDA and working capital, with annual financial statements publication set for April 22, 2026

Financial Statements EBITDA Formycon AG Preliminary Figures 2025 Fiscal Year
BRIEF

published on 03/19/2026 at 06:35, 3 months 9 days ago

Formycon obtient l'autorisation de commercialiser un biosimilaire en Europe et au-delà.

Formycon Maladies De La Rétine Expansion Du Marché Licences De Biosimilaires Règlement De Brevet
BRIEF

published on 03/19/2026 at 06:35, 3 months 9 days ago

Formycon Secures Licensing for Biosimilar in Europe and Beyond

Market Expansion Formycon Retinal Diseases Biosimilar Licensing Patent Settlement
PRESS RELEASE

published on 03/19/2026 at 06:30, 3 months 9 days ago

Formycon secures license date for aflibercept 2 mg biosimilar FYB203 in Europe and further territories following settlement with Regeneron and Bayer
Formycon secures license date for aflibercept 2 mg biosimilar FYB203 in Europe and further territories following settlement with Regeneron and Bayer

Bayer Biosimilar Formycon Regeneron Aflibercept
BRIEF

published on 03/18/2026 at 18:58, 3 months 9 days ago

Formycon AG Delays 2025 Financial Statement Publication

Regulatory Compliance Financial Statement Formycon AG Postponement 2025 Results
BRIEF

published on 03/18/2026 at 18:58, 3 months 9 days ago

Formycon AG reporte la publication de ses états financiers 2025

Formycon AG États Financiers Conformité Réglementaire Report Résultats 2025
PRESS RELEASE

published on 03/18/2026 at 18:53, 3 months 9 days ago

EQS-Adhoc: Formycon AG postpones the publication of its audited annual and consolidated financial statements for 2025
Formycon AG postpones the publication of its audited annual and consolidated financial statements for 2025 due to internal system changes, extended reconciliation work, and audit delays

Formycon AG Postponement 2025 Audited Financial Statements Internal System Changes

Published on 06/27/2026 at 16:50, 23 hours 24 minutes ago

Redwood AI Announces Definitive Agreement with Quantum.IQ and Expands into Quantum Resistant Cyber Security
Published on 06/27/2026 at 01:40, 1 day 14 hours ago

Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 1 day 16 hours ago

Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 1 day 17 hours ago

Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 1 day 17 hours ago

Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada

View all ACCESSWIRE

Published on 06/27/2026 at 00:05, 1 day 16 hours ago

EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 1 day 16 hours ago

Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 day 16 hours ago

Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 1 day 16 hours ago

EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 1 day 16 hours ago

EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE

View all EQS

Published on 06/26/2026 at 17:45, 1 day 22 hours ago

Combined General Meeting, June 25, 2026
Published on 06/26/2026 at 17:45, 1 day 22 hours ago

Assemblée générale mixte du 25 juin 2026
Published on 06/26/2026 at 17:45, 1 day 22 hours ago

Descriptif du programme de rachat d'actions
Published on 06/26/2026 at 14:44, 2 days 1 hour ago

Safran information
Published on 06/26/2026 at 14:44, 2 days 1 hour ago

Information Safran

View all LES ECHOS COMFI WIRE

News